LSV Asset Management
HAE icon

LSV Asset Management’s Haemonetics HAE Stock Holding History

LSV Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,567
Closed -$224K – 944
2019
Q1 		$224K Hold
2,567
– – ﹤0.01% 882
2018
Q4 		$256K Hold
2,567
– – ﹤0.01% 898
2018
Q3 		$294K Buy
+2,567
New +$266K ﹤0.01% 906

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

LSV Asset Management's HAE Position: Q2 2019 in Review

LSV Asset Management sold out of Haemonetics (HAE) in Q2 2019, closing a stake of 2,567 shares — an estimated $224K sold.

LSV Asset Management first reported a position in HAE in Q3 2018 and held it in 3 quarters. The position peaked at $294K in Q3 2018. 256 funds tracked by Wall St. Rank hold HAE as of Q2 2019.

  • LSV Asset Management reported no remaining Haemonetics position as of Q2 2019 after selling out during the quarter.
  • LSV Asset Management sold 2,567 Haemonetics shares in Q2 2019, an estimated $224K.
  • LSV Asset Management first reported a position in Haemonetics in Q3 2018 and held it in 3 quarters.
  • LSV Asset Management's Haemonetics position peaked at $294K in Q3 2018.
  • 256 funds tracked by Wall St. Rank held Haemonetics as of Q2 2019.

Based on LSV Asset Management's 13F filing for Q2 2019, filed 7 Aug 2019.